All In Biotech

Drug Trial Radar · NCT05074498

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Oct 8, 2021

Primary completion

Oct 13, 2022

Study completion Oct 13, 2022

Sponsor

Lead sponsor
TrueBinding, Inc.Industry
Sponsor type
Industry
First posted
Oct 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.

Conditions

  • Alzheimer's Disease

Interventions

  • TB006Drug

    intravenous infusion

  • PlaceboDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 104
  2. Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK)Time frame: Baseline and up to Day 104
  3. Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and ProteinTime frame: Baseline and up to Day 104
  4. Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea NitrogenTime frame: Baseline and up to Day 104
  5. Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1CTime frame: Baseline and up to Day 104
  6. Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and SodiumTime frame: Baseline and up to Day 104
  7. Part 1: Change From Baseline in Clinical Chemistry Parameter: ThyrotropinTime frame: Baseline and up to Day 104
  8. Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and PlateletsTime frame: Baseline and up to Day 104
  9. Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH)Time frame: Baseline and up to Day 104
  10. Part 1: Change From Baseline in Hematology Parameter: HematocritTime frame: Baseline and up to Day 104
  11. Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and ReticulocytesTime frame: Baseline and up to Day 104
  12. Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV)Time frame: Baseline and up to Day 104
  13. Part 1: Change From Baseline in Hematology Parameter: HemoglobinTime frame: Baseline and up to Day 104
  14. Part 1: Change From Baseline in Urine Potential of Hydrogen (pH)Time frame: Baseline and up to Day 104
  15. Part 1: Change From Baseline in Urine Specific GravityTime frame: Baseline and up to Day 104
  16. Part 1: Change From Baseline in UrobilinogenTime frame: Baseline and up to Day 104
  17. Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)Time frame: Baseline and Up to Day 104
  18. Part 1: Change From Baseline in Respiratory RateTime frame: Baseline and Up to Day 104
  19. Part 1: Change From Baseline in TemperatureTime frame: Baseline and Up to Day 104
  20. Part 1: Change From Baseline in Heart RateTime frame: Baseline and Up to Day 104
  21. Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart RateTime frame: Baseline and Up to Day 104
  22. Part 1: Change From Baseline in ECG ParametersTime frame: Baseline and Up to Day 104
  23. Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 104
  24. Part 1: Number of Participants With Clinically Significant Physical Examination FindingsTime frame: Up to Day 104
  25. Part 1: Number of Participants With Clinically Significant Neurological Examination FindingsTime frame: Up to Day 104
  26. Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006Time frame: Day 1 and Day 29
  27. Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006Time frame: At Days 1, 8 and 29
  28. Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006Time frame: At Days 1, 8 and 29
  29. Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006Time frame: Day 8 and Day 29
  30. Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006Time frame: At Day 29
  31. Part 1: Total Clearance (CL) of TB006Time frame: At Day 29
  32. Part 1: Volume of Distribution (Vd) of TB006Time frame: At Day 29
  33. Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006)Time frame: Day 1 (Predose), Day 8 (Predose), Day 36 and Day 104
  34. Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total ScoreTime frame: Baseline through Day 104

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Garden Grove, California

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    Delray Beach, Florida

  • Clinical Trial Site

    Lady Lake, Florida

  • Clinical Trial Site #1

    Maitland, Florida

  • Clinical Trial Site

    Maitland, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Stuart, Florida

  • Clinical Trial Site

    West Palm Beach, Florida

  • Clinical Trial Site

    Winter Park, Florida

  • Clinical Trial Site

    Winter Park, Florida

  • Clinical Trial Site

    Decatur, Georgia

  • Clinical Trial Site

    Matthews, North Carolina

  • Clinical Trial Site

    DeSoto, Texas

  • Clinical Trial Site

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.